<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327285</url>
  </required_header>
  <id_info>
    <org_study_id>2017PHB033-01</org_study_id>
    <secondary_id>CBMG-C2017004</secondary_id>
    <nct_id>NCT03327285</nct_id>
  </id_info>
  <brief_title>C-CAR011 Treatment in Subjects With ALL After HSCT</brief_title>
  <official_title>A Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Subjects With Acute Lymphoblastic Leukemia(ALL) After Hematopoietic Stem Cell Transplantation（HSCT）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective clinical study evaluating safety and efficacy of
      C-CAR011 treatment in subjects with ALL after HSCT
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study evaluating safety and efficacy of CBM.CD19-targeted chimeric antigen receptor T cells
      (C-CAR011) treatment in subjects with acute lymphoblastic leukemia(ALL) after hematopoietic
      stem cell transplantation（HSCT）. The amount of cells received：1.0-5.0×10^6CAR+T cells/kg
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TEAEs</measure>
    <time_frame>2 months</time_frame>
    <description>TEAEs evaluated after C-CAR011 infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GVHD</measure>
    <time_frame>2 months</time_frame>
    <description>GVHD evaluated after C-CAR011 infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Recurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival (OS) after C-CAR011 infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months</time_frame>
    <description>Progression free survival（PFS）after C-CAR011 infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Lymphoblastic Leukemia(ALL)</condition>
  <arm_group>
    <arm_group_label>C-CAR011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The amount of cells received：1.0-5.0×10^6 CAR+T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C-CAR011</intervention_name>
    <description>CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)</description>
    <arm_group_label>C-CAR011</arm_group_label>
    <other_name>Anti-CD19 chimeric antigen receptor T cells (C-CAR011)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 15-65 years old, male or female.

          -  Volunteered to participate in this study and signed informed consent.

          -  Meet the two populations above.

          -  Histologically diagnosed as CD19+B-ALL.

          -  100% T lymphocytes of donor.

          -  Treatment without chemotherapy and antibody therapy within 2 weeks prior to C-CAR011
             therapy.

          -  Left ventricular ejection fraction (LVEF) ≧ 50%, no evidence of pericardial effusion
             and clinically significant arrhythmias.

          -  Baseline oxygen saturation ≧ 92% on room air and with normal pulmonary function, no
             evidence of active lung infection.

          -  Expected survival ≧ 3 months.

          -  Eastern cooperative oncology group (ECOG) performance status of 0 or 1.

        Exclusion Criteria:

          -  History of allergy to cellular products.

          -  Any kind of these laboratory testing: serum total bilirubin≧2.0mg/dl, serum
             albumin&lt;35g/L, ALT, AST≧3×ULN, serum creatinine≧2.0mg/ dl,platelets&lt;20×109/L.

          -  The subjects had active aGVHD with II-IV degrees (Glucksberg degrees) or active
             moderate to severe cGVHD.

          -  Severe uncontrolled infection (mycotic, bacterial, virus and so on).

          -  Any central nervous system leukemia(CNS2, CNS3) , with insensitive to intrathecal
             injection of or radiotherapy of head/spine; but effectively controlled cases will be
             eligible.

          -  The subjects were treated CART cells or DLI after HSCT.

          -  Bone marrow failure syndrome（BMF） after allogeneic hematopoietic stem cell
             transplantation.

          -  Any genetically modified T cell therapy.

          -  History of heavy drinking, drug taking or mental disease.

          -  Participated in any other clinical trial within one month prior to enrollment.

          -  Women who are pregnant or lactating or have breeding intent in 6 months.

          -  The investigators believe that any increase in the risk of the subject or interference
             with the results of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangyu Zhao</last_name>
    <phone>010-88325949</phone>
    <email>13520122292@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Institute of Hematology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang</investigator_full_name>
    <investigator_title>Chair</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>Anti-CD19 chimeric antigen receptor T-cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

